The launch follows successful alpha evaluations that began last August, and marks the third of six IdentiTi implant systems the Carlsbad, Calif.-based company expects to launch this year.
“The commercial launch of IdentiTi-PC demonstrates continued solid progress against our commitment to accelerate growth by compelling the spine market and engaging surgeons with clinical distinction. This marks the fourth of twelve new product launches planned for 2019, an extraordinary level of development by any measure. We have built the spine market’s new organic innovation machine,” chair & CEO Pat Miles said in a prepared statement.
Alphatec’s IdentiTi implants are manufactured using a subtractive process which the company claims enables more predictable, proprietary porosity and results as well as enhanced imaging characteristics. The company touted that the implants are expected to perform better than competitive titanium implant offerings.
“The IdentiTi-PC proprietary pore structure is similar to that of cancellous bone. The porosity creates a roughness that improves initial stability through surface adhesion and facilitates bone apposition. ATEC’s product development machine has surpassed all expectations with its speed to market while holding the highest standards. It has been remarkable to observe,” Dr. Geoffrey Cronen of Florida Medical Clinic Orthopaedic Surgery said in a press release.
Earlier this month, Alphatec saw shares rise despite the medical device maker posting first quarter earnings that missed loss-per-share consensus on Wall Street.